Pink SheetThe saga of the ALS treatment Relyvrio may be generating ripple effects across the disease landscape. Alon Ben-Noon, CEO of NeuroSense Therapeutics Ltd. , which is developing PrimeC as an amyotrophic
ScripThe biopharmaceutical initial public offering pace has picked back up in the US again with five new offerings so far in December, but all of the IPOs were launched by firms that raised relatively smal